首页> 外文OA文献 >Entwicklung zellulärer Testsysteme zur Suche nach neuen Wirkstoffen gegen die Alzheimer-Krankheit
【2h】

Entwicklung zellulärer Testsysteme zur Suche nach neuen Wirkstoffen gegen die Alzheimer-Krankheit

机译:开发细胞测试系统以寻找抗阿尔茨海默氏病的新活性物质

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer's disease (AD) is a widespread, chronic and progressive neurodegenerative disorder of the central nervous system with multifactorial causes. AD treatment is currently based on three different types of drugs: extracts from the leaves of Ginkgo biloba, acetylcholinesterase inhibitors, and the N-methyl-D-aspartate receptor (NMDAR) antagonist memantine. Genetic polymorphisms of the APOE gene are well-known risk factors for the sporadic late-onset AD and can be related to a wide variety of neuropathological processes. There are structural differences between the apolipoprotein E (ApoE) isoforms. ApoE4 is the least stable isoform and much more susceptible to fragmentation compared to ApoE2 and ApoE3. Because of its unique conformation and reactivity, ApoE4 forms many neurotoxic fragments. A colorimetric bioassay was used to screen for protective effects against ApoE-induced toxicity. The N-methyl-D-aspartate receptor antagonist memantine is recommended for treatment of patients with moderate to severe AD. The therapeutic effect of memantine is thought to result from a reduction of glutamate-induced, Ca2+-mediated excitotoxicity in neurons. In the present study a bioassay was established to screen for new NMDAR antagonists using cell lines, which express the human NR1/NR2A and NR1/NR2B subunits of the NMDAR, respectively. Novel homobivalent ß-carboline derivatives, connecting two ß-carboline units by alkylene spacers in two different series, showed strong inhibitory activities with IC50 values comparable to memantine. The inhibitory activities of the homobivalent ß-carboline compounds seemed to depend on the presence of two quaternary nitrogens, the spacer length, and the ß-carboline structure. The pathogenesis of AD is currently not completely understood. Given that AD is caused by multiple factors, further extensive research is required to develop novel treatments that can slow down the progression of the disease or improve symptoms such as memory loss.
机译:阿尔茨海默氏病(AD)是一种具有多种原因的中枢神经系统广泛,慢性和进行性神经退行性疾病。 AD治疗目前基于三种不同类型的药物:银杏叶提取物,乙酰胆碱酯酶抑制剂和N-甲基-D-天冬氨酸受体(NMDAR)拮抗剂美金刚。 APOE基因的遗传多态性是偶发性迟发性AD的众所周知的危险因素,可能与多种神经病理学过程有关。载脂蛋白E(ApoE)亚型之间存在结构差异。与ApoE2和ApoE3相比,ApoE4是最不稳定的同工型,并且更容易断裂。由于其独特的构象和反应性,ApoE4形成许多神经毒性片段。比色生物测定法用于筛选针对ApoE诱导的毒性的保护作用。建议将N-甲基-D-天冬氨酸受体拮抗剂美金刚用于中度至重度AD患者的治疗。美金刚的治疗作用被认为是由于减少了谷氨酸诱导的,Ca2 +介导的神经元兴奋性毒性。在本研究中,建立了一种生物测定法,以使用分别表达NMDAR的人NR1 / NR2A和NR1 / NR2B亚基的细胞系筛选新的NMDAR拮抗剂。通过两个不同系列的亚烷基间隔基连接两个ß-咔啉单元的新型均二价ß-咔啉衍生物显示出强大的抑制活性,其IC50值可与美金刚相媲美。均二价ß-咔啉化合物的抑制活性似乎取决于两个季氮原子的存在,间隔长度和ß-咔啉结构。目前尚不完全了解AD的发病机理。鉴于AD是由多种因素引起的,需要进一步的广泛研究来开发可以减慢疾病进程或改善症状(如记忆力减退)的新疗法。

著录项

  • 作者

    Schmidtke Kai-Uwe;

  • 作者单位
  • 年度 2011
  • 总页数
  • 原文格式 PDF
  • 正文语种 deu
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号